ABSTRACT
An efficient multicomponent orthogonal protocol was developed for post-synthetic oligonucleotide modification using commercially available 2'- O-methyl ester and 2'- O-propargyl nucleoside scaffolds. Amidation of methyl esters with primary amines was achieved in the presence of 2'-propargyl groups which were utilized for subsequent copper catalyzed cycloaddition with GalNAc-azide. The methodology was applied to generate siRNA composed of multiple amide and triazole conjugates. Computational methods were used to illustrate the impact of substitution at the 2'-position. This a powerful post-oligomerization technique for rapidly introducing diversity to oligonucleotide design.
Subject(s)
Acetylgalactosamine/chemistry , Amides/chemistry , Azides/chemistry , Copper/chemistry , Cycloaddition Reaction/methods , Oligonucleotides/chemistry , RNA, Small Interfering/chemistry , Acetylgalactosamine/chemical synthesis , Amides/chemical synthesis , Azides/chemical synthesis , Catalysis , Click Chemistry/methods , Esterification , HeLa Cells , Humans , Models, Molecular , Oligonucleotides/chemical synthesis , RNA, Small Interfering/chemical synthesis , Triazoles/chemical synthesis , Triazoles/chemistryABSTRACT
The cytosolic conversion of therapeutically relevant nucleosides into bioactive triphosphates is often hampered by the inefficiency of the first kinase-mediated step. Nucleoside monophosphate prodrugs can be used to bypass this limitation. Herein we describe a novel cyclic-disulfide class of nucleoside monophosphate prodrugs with a cytosol-specific, reductive release trigger. The key event, a charge-dissipating reduction-triggered cyclodeesterification leads to robust cytosolic production of the cyclic 3',5'-monophosphate for downstream enzymatic processing. The antiviral competence of the platform was demonstrated with an O-benzyl-1,2-dithiane-4,5-diol ester of 2'-C-methyluridine-3',5'-phosphate. Both in vitro and in vivo comparison with the clinically efficacious ProTide prodrug of 2'-deoxy-2'-α-fluoro-ß-C-methyluridine is provided. The cytosolic specificity of the release allows for a wide range of potential applications, from tissue-targeted drug delivery to intracellular imaging.
Subject(s)
Cytosol/chemistry , Disulfides/chemistry , Drug Delivery Systems , Prodrugs/chemistry , Molecular ConformationABSTRACT
Current modifications used in small interfering RNAs (siRNAs), such as 2'-methoxy (2'-OMe) and 2'-fluoro (2'-F), improve stability, specificity or immunogenic properties but do not improve potency. These modifications were previously designed for use in antisense and not siRNA. We show, for the first time, that the siRNA-optimized novel 2'-O modifications, 2'-O-benzyl, and 2'-O-methyl-4-pyridine (2'-O-CH2Py(4)), are tolerated at multiple positions on the guide strand of siRNA sequences in vivo. 2'-O-benzyl and 2'-O-CH2Py(4) modifications were tested at each position individually along the guide strand in five sequences to determine positions that tolerated the modifications. The positions were combined together and found to increase potency and duration of siRNAs in vivo compared to their unmodified counterparts when delivered using lipid nanoparticles. For 2'-O-benzyl, four incorporations were tolerated with similar activity to the unmodified siRNA in vivo, while for 2'-O-CH2Py(4) six incorporations were tolerated. Increased in vivo activity was observed when the modifications were combined at positions 8 and 15 on the guide strand. Understanding the optimal placement of siRNA-optimized modifications needed for maximal in vivo activity is necessary for development of RNA-based therapeutics.
ABSTRACT
The RNA induced silencing complex (RISC) contains at its core the endonuclease Argonaute (Ago) that allows for guide strand (GS)-mediated sequence-specific cleavage of the target mRNA. Functionalization of the sugar/phosphodiester backbone of the GS, which is in direct contact with Ago, presents a logical opportunity to affect RISC's activity. A systematic evaluation of modified nucleosides requires the synthesis of phosphoramidites corresponding to all four canonical bases (A, U, C, and G) and their sequential evaluation at each position along the 21-nucleotide-long GS. With the use of a platform approach, the sequential replacement of canonical bases with inosine greatly simplifies the problem and defines a new activity baseline toward which the corresponding sugar-modified inosines are compared. This approach was validated using 2'-O-benzyl modification, which demonstrated that positions 5, 8, 15, and 19 can accommodate this large group. Application of this high-throughput methodology now allows for hypothesis-driven rational design of highly potent, immunologically silent and stable siRNAs suitable for therapeutic applications.
Subject(s)
Nucleosides/chemistry , RNA Interference , Base Sequence , Molecular Sequence Data , Molecular Structure , Nucleosides/geneticsABSTRACT
A series of novel 1-aminocyclopentyl-3-carboxyamides incorporating substituted tetrahydropyran moieties have been synthesized and subsequently evaluated for their antagonistic activity against the human CCR2 receptor. Among them analog 59 was found to posses potent antagonistic activity.
Subject(s)
Chemistry, Pharmaceutical/methods , Receptors, CCR2/antagonists & inhibitors , Receptors, CCR2/chemistry , Administration, Oral , Animals , Chemotaxis , Dogs , Drug Design , Humans , Inhibitory Concentration 50 , Macaca mulatta , Models, Chemical , Molecular Structure , Rats , Rats, Sprague-Dawley , Structure-Activity RelationshipABSTRACT
In an effort to shed light on the active binding conformation of our 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists, we prepared several conformationally constrained analogs resulting from backbone cyclization. Evaluation of CCR2 binding affinities for these analogs gave insight into the optimal relative positions of the piperidine and benzylamide moieties while simultaneously leading to the discovery of a new, potent lead type based upon a spirocyclic acetal scaffold.
Subject(s)
Cyclopentanes/chemistry , Receptors, CCR2/antagonists & inhibitors , Spiro Compounds/chemistry , Acetals/chemistry , Acetals/pharmacology , Crystallography, X-Ray , Cyclopentanes/pharmacology , Humans , Kinetics , Molecular Conformation , Monocytes/drug effects , Monocytes/metabolism , Receptors, CCR2/metabolism , Spiro Compounds/pharmacology , Structure-Activity RelationshipABSTRACT
As a part of an ongoing medicinal chemistry effort to identify inhibitors of the Hepatitis C Virus RNA replication, we report here the synthesis and biological evaluation of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine. The parent 2'-C-methyladenosine shows excellent intracellular inhibitory activity but poor pharmacokinetic profile. Replacement of the nucleoside-defining 9-N of 2'-C-methyladenosine with a carbon atom was designed to yield metabolically more stable C-nucleosides. Modifications at position 7 were designed to exploit the importance of the hydrogen bond accepting properties of this heteroatom in modulating the adenosine deaminase (ADA) mediated 6-N deamination. 7-Oxa-7,9-dideaza-2'-C-methyladenosine was found to be a moderately active inhibitor of intracellular HCV RNA replication, whereas 9-deaza- 2'-C-methyladenosine showed only weak activity despite excellent overlap of both of the synthesized target compounds with 2'-C-methyladenosine's three dimensional structure. Position 7 of the nucleobase proved to be an effective handle for modulating ADA-mediated degradation, with the rate of degradation correlating with the hydrogen-bonding properties at this position.
Subject(s)
Adenosine/analogs & derivatives , Adenosine/pharmacology , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Hepacivirus/drug effects , Adenosine/chemistry , Cell Line , Hepacivirus/metabolism , Humans , Models, Molecular , Molecular Structure , RNA, Viral/metabolism , Virus ReplicationABSTRACT
A series of low molecular weight antagonists of both the human and murine CC chemokine receptor 2, containing a 1-alkyl-3-(3-methyl-4-spiroindenylpiperidine)-substituted cyclopentanecarboxamide, is described. A SAR study of the C(1) substituent revealed that short, branched alkyl groups such as isopropyl, isobutyl, or cyclopropyl are optimal for both human and murine CCR2 binding activity.
Subject(s)
Amides/chemistry , Amides/chemical synthesis , Carbon/chemistry , Chemistry, Pharmaceutical/methods , Cyclopentanes/chemistry , Cyclopentanes/chemical synthesis , Receptors, Chemokine/antagonists & inhibitors , Receptors, Chemokine/metabolism , Animals , Drug Design , Humans , Inhibitory Concentration 50 , Leukocytes/metabolism , Male , Mice , Molecular Weight , Rats , Rats, Sprague-Dawley , Receptors, CCR2 , Structure-Activity RelationshipABSTRACT
Introduction of ring restrictions to a linear aminobutyramide CC chemokine receptor 2 (CCR2) antagonist lead (2) led to the discovery of a 1,3-disubstituted cyclopentane scaffold with enhanced hCCR2 receptor binding and antagonist activity. (1S,3R)-N-[3,5-Bis(trifluoromethyl)benzyl]-1-methyl-3-[(1R,3'R)-methyl-1'H-spiro[indene-1,4'-piperidin]-1'-yl]cyclopentanecarboxamide (16) had IC50 of 1.3 nM (binding) and 0.45 nM (functional chemotaxis) against hCCR2. It also showed activity against the mouse CCR2 receptor with an IC50 of 130 nM. Compound 16 is selective against other chemokine receptors, including CCR5 ( approximately 500-fold).
Subject(s)
Amides/chemical synthesis , Cyclopentanes/chemical synthesis , Piperidines/chemical synthesis , Receptors, Chemokine/antagonists & inhibitors , Amides/chemistry , Amides/pharmacology , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclopentanes/chemistry , Cyclopentanes/pharmacology , Humans , In Vitro Techniques , Mice , Monocytes/drug effects , Monocytes/metabolism , Piperidines/chemistry , Piperidines/pharmacology , Receptors, CCR2 , Stereoisomerism , Structure-Activity RelationshipABSTRACT
A systematic examination of the central aromatic portion of the lead (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(1'H-spiro[indene-1,4'-piperidin]-1'-yl)butanamide (9) led to the discovery of a novel class of CCR2 receptor antagonists, which carry small alicyclic groups such as cyclopropyl, cylobutyl, or cyclopropylmethyl attached at C2 of the carbon backbone. The most potent compound discovered, namely (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-cyclopropyl-4-[(1R,3'R)-3'-methyl-1'H-spiro[indene-1,4'-piperidin]-1'-yl]butanamide (29), showed very high binding affinity (IC50 = 4 nM, human monocyte) and excellent selectivity toward other related chemokine receptors. The excellent pharmacokinetic profile of this new lead compound allows for extensive in vivo evaluation.
Subject(s)
Amides/chemistry , Amides/pharmacokinetics , Receptors, Chemokine/antagonists & inhibitors , Alkylation , Amides/chemical synthesis , Amination , Animals , Cells, Cultured , Cricetinae , Humans , Molecular Structure , Rats , Rats, Sprague-Dawley , Receptors, CCR2 , Receptors, Chemokine/metabolism , Structure-Activity RelationshipABSTRACT
Systematic modification of a screening lead yielded a class of potent glycinamide based CCR2 antagonists. The best compound (55, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-{[2-(1-piperidinyl)ethyl]amino}-2-(3-thienyl)acetamide) displayed good binding affinity (IC50=30 and 39 nM) toward human monocytes and CHO cell expressing human CCR2b, respectively. Functionally, it blocked MCP-1 (CCL2)-induced calcium mobilization (IC50=50 nM) and chemotaxis mediated through the CCR2 receptor (9.6 nM). It is selective against other chemokine receptors tested.
Subject(s)
Glycine/analogs & derivatives , Monocytes/drug effects , Receptors, Chemokine/antagonists & inhibitors , Animals , Binding Sites , CHO Cells/drug effects , Calcium/metabolism , Chemokine CCL2/antagonists & inhibitors , Chemokine CCL2/metabolism , Cricetinae , Glycine/chemical synthesis , Glycine/chemistry , Glycine/pharmacology , Humans , Inhibitory Concentration 50 , Models, Biological , Receptors, CCR2 , Receptors, Chemokine/metabolismABSTRACT
Several vinyl halides previously used in inositol syntheses were subjected to electrochemical reduction. The unreactivity of allylic alcohols or allylic ethers at the applied potentials allowed the selective reduction of vinyl halides to olefins. Electrochemical methods provide for selective reduction of vinyl iodides over vinyl bromides, with better yields than analogous tin methodology. Cinnamyl ethers were reductively cleaved at -3.2 V (vs Ag/AgNO(3)) in the presence of alkyl allyl ethers to provide selective deprotection. The electrochemical reduction of vinyl halides in the presence of a vinyloxirane or vinylaziridine is accompanied by the solvolysis of the strained rings. Yields and conditions are reported and compared to those from standard tin-induced dehalogenation.
